Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART).
Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH 2 O and peak pressure of 60 cmH 2 O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure ≤30 cmH 2 O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.
Trial registration: ClinicalTrials.gov Identifier: NCT01374022 Keywords: Acute respiratory distress syndrome, Alveolar recruitment, PEEP, Mechanical ventilation, Clinical trials, Randomized Background Acute respiratory distress syndrome (ARDS) is a common problem in critically-ill patients, associated with inhospital mortality between 41% and 58% [1] [2] [3] and reduced quality of life among survivors [4, 5] . Although mechanical ventilation provides essential life support, it can worsen lung injury [6] . Mechanisms of ventilatorinduced lung injury include regional alveolar overdistention, repetitive alveolar collapse with shearing (atelectrauma), and oxygen toxicity [7, 8] .
Ventilation with low tidal volumes (≤6 mL/kg) and targeting plateau pressures of 30 cmH 2 O or less improves survival compared to the use of high volumes (12 mL/kg), confirming the relevance of avoiding overdistention in ARDS [9] . Although this strategy improved care of ARDS patients, mortality is still unacceptably high [3] . Experimental data suggest that atelectrauma is prominent in ARDS [10, 11] and may be a contributor to ARDS mortality [12] . Opening of collapsed lung tissue by recruitment maneuvers and preventing further collapse by using titration of PEEP may prevent atelectrauma. Maximum alveolar recruitment followed by PEEP titration is a relatively simple and widely available intervention.
Some studies demonstrated that maximum recruitment strategy, achieving PEEP of 45 cmH 2 O and peak pressure of 60 cmH 2 O, can fully recruit the lung and reverse hypoxemia in most ARDS patients, without major adverse events [13, 14] . However, a systematic review of alveolar recruitment maneuvers found only four randomized trials and was inconclusive regarding the effect of recruitment maneuvers on survival and other patients' relevant outcomes [15] . Recently a pilot study randomized 20 patients to an alveolar recruitment maneuver with progressive PEEP elevation up to 40 cmH 2 O and peak pressure of 55 cmH 2 O plus PEEP titrated according to peripheral oxygen saturation or to ARDSNet strategy [16] . There were a decrease in some systemic cytokines, and improvement in oxygenation and compliance. As expected, the trial was not powered to and did not show any difference in mortality and other clinical outcomes. Therefore, a trial with high methodological quality and power to assess whether maximum alveolar recruitment followed by ventilation with titrated PEEP improves clinical outcomes in ARDS patients is highly needed.
Methods

Objectives
Our primary objective is to determine if maximum alveolar recruitment associated with PEEP titrated according to the static compliance of the respiratory system (ART strategy) increases 28-day survival rate of patients with acute respiratory distress syndrome compared to conventional treatment (ARDSNet strategy).
Secondary objectives are to evaluate the effect of the ART strategy compared to ARDSNet strategy on the following outcomes: length of hospitalization; pneumothorax requiring chest tube at 7 days; barotrauma (any pneumothorax, pneumomediastinum, subcutaneous emphysema or pneumatocele >2 cm after randomization) at 7 days; ventilator-free days from days 1 to 28; intensive care unit, in-hospital, and 6-month survival.
Study design
ART is a randomized, stratified, multicenter trial with allocation concealment and intention-to-treat analysis. Patients with ARDS will be treated with a stepwise maximum alveolar recruitment maneuver followed by ventilation with optimal PEEP (ART Strategy) vs. a conventional approach (ARDSNet Strategy). This is an event-guided trial which will end when 520 events (deaths within 28 days) are observed. Patients will be followed up to 6 months, although the main outcome is determined at the 28-day follow-up.
Screening
Eligibility will be evaluated in two phases: screening phase and defining eligibility phase.
In the screening phase, patients will be considered for inclusion in the study if they are receiving invasive mechanical ventilation and have ARDS of less than 72 h duration. All of the following criteria should be met [17] : acute onset respiratory failure; bilateral pulmonary infiltrate on chest X-ray compatible with pulmonary edema; severe hypoxemia, defined as PaO 2 /FiO 2 ≤200 in arterial blood gases for less than 72 h; absence of left atrial hypertension based on the medical team's evaluation (clinical or echocardiographic signs); and presence of a risk factor for lung injury.
The following are exclusion criteria (exclusion if any one present): age <18 years; use of vasoconstrictor drugs in increasing doses over the past 2 h (norepinephrine increase ≥0,5 mcg/kg/min or dopamine increase ≥5 mcg/kg/min) or mean arterial pressure <65 mmHg; this may be a transient criterion, since patients meeting this criterion might be included later if hemodynamics improves; contraindications to hypercapnia such as intracranial hypertension or acute coronary syndrome; and undrained pneumothorax or subcutaneous emphysema.
While waiting for the consent of a legal representative or for at least 3 h, we suggest to ventilate patients using a conventional approach as follows [9] : volume-controlled mode, tidal volume of 4 to 6 mL/kg of predicted body weight to ensure plateau pressure ≤30 cmH 2 O, PEEP, and FiO 2 adjusted according to the ARDSNet 
Defining eligibility
Right after obtaining informed consent, ventilator will be set as described above (if the recommended ventilation were not set yet) and FiO 2 will be adjusted to 100% and PEEP to 10 cmH 2 O (except if previous PEEP were ≥16 cmH 2 O; in this case PEEP will be maintained). Arterial blood gases will be measured after 30 min.
Patients will be considered eligible if the PaO 2 measured with FiO 2 = 100% and PEEP = 10 cmH 2 O (or ≥16 cmH 2 O) is 200 mmHg or less, and less than 72 h have been spent since the first time a PaO 2 /FiO 2 ≤200 was determined.
Criteria for withdrawal of patients from the trial
The withdrawal of a patient from the study will occur only if consent is withdrawn by the patient, his/her legal representative, or the patient's primary care physician.
Treatment should be discontinued if the patient is sufficiently unstable to contraindicate the continued use of high PEEP levels. The necessary measures to minimize instability and adverse effects caused by the use of high PEEP levels should be implemented as deemed appropriate by the medical team. However, patient follow-up will proceed normally, that is, the patient will not be excluded from follow-up and analyses.
Randomization and allocation concealment
Patients will be randomized in a 1:1 ratio to the ART strategy or the ARDSNet strategy.
The random allocation list was generated in blocks (number of treatments per block will be kept confidential to avoid prediction of future patients' allocation) and was stratified by investigator center age, and PaO 2 /FiO 2 ratio (≤100 or >100). Allocation concealment will be maintained by means of a web-based central, automated randomization system, available 24 h a day (ACT-Clinic), developed by a team of programmers and investigators from the Research Institute at Hospital do Coração (IEP-HCor). The group to which the patient will be allocated will only be disclosed after patient enrollment information is recorded in the electronic system. This prevents the investigator and the medical team from predicting to which treatment group the patient will be allocated. To include a patient in the study, investigators must simply access the IEP-HCor website (https://servicos.hcor.com.br/ iep/estudoclinico), log in with individual username and password, and fill in a short medical record form.
Interventions Table 2 summarizes the procedures that will be used for ART and ARDSNet groups in this study.
ART strategy (maximum alveolar recruitment maneuver plus PEEP titration)
If patients are assigned to the ART strategy, the following steps should be observed ( Figure 1 ):
Preparation for the recruitment maneuver
Patients will be sedated, paralyzed (with a neuromuscular blocker), and kept in supine position. Closed endotracheal suction system will be installed.
Monitoring will be provided with at least: heart rate, cardiac rhythm, periferic oxygen saturation, and blood pressure (preferably invasive method). Hypovolemia will be corrected by crystalloid or colloid infusion until variation of arterial pulse pressure ≤13%, or central venous pressure of >10 cmH 2 O if variation of arterial pulse pressure measurement is not available. If the variation of arterial pulse pressure method is used, we recommend to transiently setting tidal volume to 8 mL/kg for 15 min before measurements 2. Maximum alveolar recruitment maneuver Mechanical ventilator will be set to pressurecontrolled mode with FiO 2 of 100%; respiratory rate of 10/min and I:E ratio of 1:1. Alveolar recruitment maneuver steps are described below:
Recruitment starts with PEEP of 25 cmH 2 O and driving pressure of 15 cmH 2 O. These parameters will be maintained for 1 min; Following this, PEEP will be increased to 35 cmH 2 O with other parameters maintained for 1 min; Lastly, PEEP will be increased to 45 cmH 2 O with other parameters maintained for 2 min.
Recruitment will be terminated if one or more of the following signs of clinical deterioration are observed: 
PEEP titration and new recruitment
Right after completing recruitment, PEEP will be set to 23 cmH 2 O. Ventilatory mode will be set to Lung recruitment Figure 1 ART strategy: maximum alveolar recruitment maneuver associated with PEEP titration.
The ART Investigators Trials 2012, 13:153 volume-controlled, tidal volume to 5 mL/kg of predicted body weight, respiratory rate to 20/min, flow to 30 L/min (square wave) and FiO 2 to 100%. After 4 min, static compliance of the respiratory system will be calculated and recorded (inspiratory pause ≥2 s required to reach plateau pressure). In sequence, PEEP will be decreased in steps of 20, 17, 14, and 11 cmH 2 O and the corresponding static compliance of the respiratory system will be recorded after each 4 min. Optimal PEEP will be the PEEP associated with the best static compliance plus 2 cmH 2 O. If a 'plateau' of best compliance is achieved, that is, more than one PEEP level associated with the best compliance, then the higher of the PEEP levels within the 'plateau' plus 2 cmH 2 O is considered the optimal PEEP. If falls in compliance are verified in two consecutive steps, the PEEP level with the highest compliance plus 2 cmH 2 O is the optimal PEEP. In this case, there is no need to measure compliance on lower PEEP levels. After the PEEP titration phase, a new alveolar recruitment will be performed. The mechanical ventilator will be reset to pressure-controlled mode; respiratory rate to 10/min; I:E ratio to 1:1, driving pressure to 15 cmH 2 O, FiO 2 to 100% and PEEP adjusted to 45 cmH 2 O. These parameters will be maintained for 2 min.
Maintenance ventilation
Following the new alveolar recruitment, the maintenance ventilation will be set: volumecontrolled mode, tidal volume of 5 mL/kg of predicted body weight. If plateau pressure >30 cmH2O, reduce to 4 mL/kg of predicted body weight. Minimum and maximum tidal volumes are 4 mL/kg and 6 mL/kg of predicted body weight. Flow of 60 L/min, descending waveform, inspiratory pause of 0.5 s, I:E ratio of 1:1 to 1:2, respiratory rate to maintain the same minute ventilation prior to randomization, PEEP adjusted to optimal PEEP (PEEP value at maximum compliance plus 2 cmH 2 O) and FiO 2 adjusted for SpO 2 ≥90% and ≤95%.
When to repeat a recruitment maneuver
Repetition of the maximum alveolar recruitment maneuver will be considered only when the initial maneuver is successful, which we defined as an increase of PaO 2 /FiO 2 ratio >100 after maneuver.
If the initial maneuver is successful, it will be repeated in two situations:
Every 24 h if PaO 2 /FiO 2 ratio is <250 and a decrease in PaO 2 /FiO 2 ratio >50 occurs. After the recruitment maneuver, PEEP should be set at the value it was before plus 2 cmH 2 O. That is, there is no need to titrate PEEP again.
If an accidental disconnection of the respiratory circuits occurs and PEEP is ≥12 cmH 2 O. After the recruitment maneuver, PEEP should be set at the same level it was before disconnection. There is no need to titrate PEEP again.
6. Adjustments in tidal volume and respiratory rate Adjustments in tidal volume and respiratory rate are the same for ART group and ARDSNet group, and is described below. Respiratory rate and tidal volume must be adjusted to achieve the arterial pH goal: between 7.30 and 7.45. The pH is measured when clinically indicated.
Management of alkalemia and acidemia
Alkalemia ( Daily assessments to attempt the spontaneous breathing test will be performed preferably during the morning. The criteria shown on Table 3 ARDSNet strategy (conventional ventilation)
Maintenance ventilation
If patients are assigned to the ARDSNet strategy, no alveolar recruitment will be performed. The conventional mechanical ventilation strategy that will be used in this group has been described previously [9, 18] . Initial ventilator settings will be: 2. Adjustments in tidal volume and respiratory rate These are the same as described for the ART Group above. The definition of refractory hypoxemia is the same as for the ART group, that is, a PaO 2 < 55 mmHg or SpO 2 < 88% with FiO 2 = 100%. The sequence of actions to be taken for patients presenting with refractory hypoxemia is similar, except for the first two steps, as is describe below:
Refractory hypoxemia
Increase PEEP up to 24 cmH 2 O and FiO 2 to 100% (as in the right end of the ARDSNet 
Weaning from mechanical ventilation
Weaning of PEEP and FiO 2 is done following the ARDSNet table (Table 1) .
Other aspects of weaning are the same as described above for the ART group.
Blinding
Since the intervention will be administered to criticallyill patients on mechanical ventilation (that is, mostly sedated), blinding of these patients is not necessary. Because this is a non-pharmacological intervention, blinding of the medical team is not feasible. There is no need for a committee to validate the primary study outcome (28-day survival), and therefore outcome adjudicators will not be blinded.
Outcomes
The primary outcome of the ART is 28-day survival. The secondary outcomes are: (1) length of ICU stay; (2) length of hospital stay; (3) pneumothorax requiring chest tube at 7 days; (4) barotrauma (any pneumothorax, pneumomediastinum, subcutaneous emphysema, or pneumatocele > 2 cm after randomization) at 7 days; (5) mechanical ventilation-free from days 1 to 28; (6) ICU survival; (7) in-hospital survival; and (8) 6-month survival.
Data collection and management
Study follow-up and the variables that will be collected are described below.
Screening and eligibility data (Day 0)
Patient's initials, gender, date of birth Verification of ARDS criteria Screening inclusion and exclusion criteria Respiratory variables (tidal volume, plateau pressure, total respiratory rate, PEEP, FiO 2 ) while awaiting informed consent Final eligibility criteria: PaO 2 at FiO 2 of 100% and PEEP of 10cmH 2 O (or greater if previous PEEP were ≥16cmH 2 O) Estimated time from onset of ARDS (onset of ARDS based on arterial blood gases until randomization)
Baseline Data (Day 0)
The following data will be recorded at the baseline visit:
Weight (measures with a weighing scale) Height SAPS 3 (at ICU admission) Respiratory variables (Tidal volume, Plateau pressure, Total respiratory rate, PEEP, FiO 2 ) Sequential organ failure assessment (SOFA) Cause of ARDS Days of intubation prior randomization Treatment Data (1 h after start of intervention)
The following data regarding treatment will be assessed for patients randomized to ART strategy:
Alveolar recruitment (for the group treated with maximum alveolar recruitment) Maximum PEEP reached If maximum alveolar recruitment is interrupted, the reason provided (list of criteria for interruption) The following data regarding treatment will be assessed for all patients: Respiratory variables of maintenance ventilation (Tidal volume, Plateau pressure, Total respiratory rate, PEEP, FiO 2 , PaO 2 , PaCO 2 , Arterial pH) Hemodynamic variables (Heart rate, Mean blood pressure, Use of noradrenaline and dopamine)
1-Day Follow-Up
Respiratory variables of maintenance ventilation (Tidal volume, Plateau pressure, Total respiratory rate, PEEP, FiO 2 , PaO 2 , PaCO 2 , Arterial pH) Water balance and weight (weighing scale)
3-Day Follow-Up
7-day follow-up
Vital status at day 7. If patient dies before day 7, the following variables should be collected:
Date of death Death due to refractory hypoxemia Death due to refractory respiratory acidosis Death due to refractory barotrauma Number of days on mechanical ventilation
Respiratory variables of maintenance ventilation (Tidal volume, plateau pressure, total respiratory rate, PEEP, FiO 2 , PaO 2 , PaCO 2 , arterial pH) Water balance and weight (weighing scale) Co-interventions during the period (use of/ number of days using neuromuscular blockers; use of/number of days using continuous infusion of sedatives; use of/number of days using continuous infusion of narcotics; use of/number of days using noradrenaline or dopamine; use of/ number of days using corticoids; rescue therapies for refractory hypoxemia: prone position, nitric oxide, high frequency oscillatory ventilation, ECMO) Pneumothorax requiring chest tube drainage during the period Barotrauma (any pneumothorax, pneumomediastinum, subcutaneous emphysema, or pneumatocele > 2 cm after randomization) during the period
Hospital discharge
Date of ICU discharge and vital status at ICU discharge Date of hospital discharge and vital status at hospital discharge
28-day follow-up
Days on mechanical ventilation (considering the first 28 days after randomization) Vital status and date of death (for patients who died)
6-month follow-up
Vital status and date of death (for patients who died)
Clinical Data Management System (CDMS) and quality control
Besides the 24-h concealed randomization, the ACT Clinic will provide data entry, data cleaning, and exportation for analysis. The system will also provide reports on the status of the study forms (completed forms, overdue forms), weekly study recruitment by center, and graphs of observed and expected cumulative recruitment. Several procedures will assure data quality, including: (1) all investigators will attend a training session before the start of the study to standardize procedures, including data collection; (2) the investigators may contact the Study Coordinating Center to solve issues or problems that may arise; (3) data entry into the ACT-Clinic is subject to various checks for missing data, plausible, possible or non-permitted value ranges, and logic checks. Problems are informed by the system at the time of data entry; (4) statistical techniques to identify inconsistencies will be applied periodically (about every two weeks). The centers will be notified of the inconsistencies and asked to correct them; (5) statistical routines to identify fraud will be conducted periodically (every 90 days); (6) on-site monitoring will be conducted during study conduction; (7) the coordinating center will review detailed reports on screening, enrolment, follow-up, inconsistencies, and completeness of data. Immediate actions will follow to solve problems that arise.
Sample size
ART is an event driven study designed to last until 520 events (deaths within 28 days) are observed. This number of events is sufficient to detect a hazard ratio of 0.75 (that is, relative reduction in event rate of 25%), considering a type I error of 5%, 90% power, and a similar allocation of subjects to each group. Considering an event rate in the control group of 36% (mean proportion of deaths in randomized studies conducted after 1994, when the definition of ARDS was first standardized) [3] we expect that about 1,620 patients will be needed to achieve the number of events planned. However, since this is an event driven study, the total sample size can vary depending on the event rate in the experimental and control groups.
Statistical analysis plan
All analysis will follow the intention-to-treat principle. Survival within 28 days (primary outcome) in both groups will be assessed using Kaplan-Meier curves and Cox proportional hazard models, without adjustment for other co-variates. Treatment effects on length of ICU stay, hospital stay, and number of mechanical ventilation-free days at 28 days will be analyzed using Mann-Whitney tests. Occurrence of pneumothorax and barotrauma will be evaluated using chi-square tests; ICU and in-hospital mortality will be evaluated with chisquare tests; 6-month survival will be analyzed using Kaplan-Meier curves and Cox proportional hazards models. Treatment effect on 28-day survival will be analyzed in the following subgroups: (1) PaO 2 /FiO 2 ≤100 vs. >100; (2) SAPS 3 score <50 vs. ≥50; 3) (pulmonary ARDS (pneumonia, aspiration, pulmonary contusion, near drowning) vs. extrapulmonary ARDS (non-pulmonary sepsis, trauma without pulmonary contusion, major surgery, multiple transfusions, traumatic brain injury, drug overdose, shock, other cause) (4) time of ARDS ≤36 h vs. >36 to <72 h; (5) mechanical ventilation ≤2 days, 3 to 4 days, ≥5 days. Effects on subgroups will be evaluated using the chi-square test for homogeneity. Statistical significance is defined as P < 0.05. All analyses will be carried out using the statistical software R (R Development Core Team, URL http://www. R-project.org -version 2.13) or STATA SE 11 for Windows (College Station, TX, USA).
Ethical aspects
Each investigator center will submit the study protocol to its institutional Research Ethics Board (REB). The study should start only after being approved by the REB. Written informed consent will be obtained from a legal representative of all participants. This study is in compliance with Brazilian and international declarations.
Trial organization and management Trial management team (TMT)
A team based on the Research Institute HCor, São Paulo, Brazil will manage the trial on a day-to-day basis. The TMT is comprised by the chief investigator, a project manager, a statistician, and a computer programmer.
The responsibilities of the TMT include:
Planning and conducting the study: designing the protocol; designing the electronic case report forms (e-CRF); designing the operation guide; managing and controlling data quality; designing, testing, and maintaining the electronic data capture system; continuous data quality control; assisting the steering committee; Managing the research centers: selecting and training the research centers; helping the centers prepare a regulatory report to be submitted to the REBs and assisting the centers with the submission; monitoring recruitment rates and the actions to increase recruitment; monitoring follow-up and implementing actions to prevent follow-up losses; auditing; sending study materials to the research centers; producing a monthly study newsletter; developing supporting material for the study;
Statistical analysis and research reporting: complete statistical analysis; helping to write the final manuscript.
Trial steering committee (TSC)
The TSC is responsible for the overall study supervision, assisting in developing the study protocol and preparing the final manuscript. All other study committees report to the TSC. The TSC members are investigators trained in designing and conducting randomized clinical trials, intensivists, respiratory therapists, and pulmonologists experienced in conducting multicenter randomized studies on ARDS.
Trial centers
Initially 80 centers would be invited to participate in the study, but the current goal is to involve 120 centers in the study. Details of the centers which accepted to participate in the trial at the time of this manuscript submission are given in the Appendix.
Institutional support from the Brazilian Association of Intensive Care Medicine (Associação de Medicina Intensiva Brasileira (AMIB))
The AMIB supports the ART study by means of the AMIB-Net. The AMIB-Net will assist with the selection and invitation of centers to participate in the ART, as well as facilitate the organization of meetings of researchers during national scientific meetings organized by the AMIB.
Publication policy
The ART study success depends on all its collaborators. Therefore, the primary results of the trial will be published under the name of ART Investigators. The contributions of all collaborators, their names and respective institutions, will be acknowledged in the manuscript. To safeguard the scientific integrity of the study, data from this study will be submitted to publication only after the final approval from the TSC.
Data monitoring committee (DMC)
The DMC is set up with independent epidemiologists and intensivists. The DMC is in charge of providing recommendations for the TSC of continuing the study as planned or discontinuing the recruitment based on evidence that the intervention causes increased mortality in the experimental group as compared to the control group. Interim analyses will be conducted after recruitment of approximately 33% and 66% of the sample. Based on these interim analyses, and, occasionally, on external evidence, the DMC shall decide whether there is evidence beyond a reasonable doubt that the treatment is clearly contraindicated in all patients or any subgroup. The criterion of evidence beyond a reasonable doubt is increased mortality at 28 days with the maximum lung recruitment strategy compared with the low PEEP strategy, with P <0.01. Otherwise, the TSC and other investigators will not be informed of the results of interim analyses. Considering previous evidence showing that: (1) early discontinuation of randomized trials due to benefits tends to produce biased estimates of effect (overestimation of the true effect), leading to erroneous medical guidelines and decisions [19] ; (2) according to the ethical principle of non-maleficence, a new treatment should not be used until there is clear, objective evidence that it is beneficial; (3) clinical practice usually does not change unless there is fairly convincing evidence of the advantages of the new treatment, which would be undermined if the study is discontinued early due to benefits; the decision of early discontinuation of the experimental treatment due to benefits may not be advantageous for future patients, or may contribute to mislead guidelines [20] . For these reasons, early discontinuation of the study due to benefits of the experimental treatment is not planned.
Discussion
ARDS is a common problem in intensive care associated with a very large in-hospital mortality rate, in spite of advances in therapy [3] . Maximum alveolar recruitment followed by PEEP titration is a relatively simple, inexpensive, and widely available intervention with potential to improve the prognosis of patients with ARDS. In most patients with ARDS, this strategy is able to keep open more than 90% of lung mass, improving oxygenation and preventing atelectrauma [13] . However, the effects of this strategy on patient important outcomes remain to be established. Therefore, evidence from well designed and conducted trials to solve this question is essential.
The ART was planned to be the largest randomized trial involving ARDS patients conducted to date. It will provide a precise and reliable estimate of the effect of alveolar recruitment and PEEP titration on survival of ARDS patients compared to the ARDSNet strategy, currently the evidence-based best approach for mechanical ventilation.
If our study finds that the maximum alveolar recruitment plus PEEP titration is not beneficial, this will play a role in changing medical practice since maximum alveolar recruitment associated with high levels of PEEP is routinely used by many intensivists. On the other hand, if the study demonstrates that maximum alveolar recruitment associated with PEEP titration increases survival in patients with ARDS, this will represent a valuable improvement for the treatment of ARDS patients.
Trial status
The ART is currently ongoing in 103 sites in Brazil, Colombia, Italy, and Mexico. Enrollment started in December 2011 in one site. Now, 40 sites are actively screening for patients, and the remaining are undergoing REB evaluation. As of June 1, 2012, we had already enrolled 63 patients. We are inviting centers in other countries to join us.
